Then, we propose that disruption of mitochondrial complex III mediated by mutant SF3B1 could be dependent on the cellular context, and the metabolic consequences of SF3B1 mutations in CD34+ of MDS patients still of major importance. This evidence concerns the gene CD34 and myelodysplastic syndrome.